Oligodendroglial tumor chemotherapy using "decreased-dose-intensity" PCV: a Singapore experience.

A U Ty, S J See, J P Rao, J B K Khoo, M C Wong

Journal: Neurology 2006;66(2):247-9

PMID: 16434664

Abstract

The authors propose "decreased-dose-intensity" PCV (procarbazine, lomustine [CCNU], and vincristine) chemotherapy for Asian patients with oligodendroglial tumors. In this study, all seven patients with oligodendroglioma (OD) and eight with anaplastic oligodendroglioma (AO) had objective responses or stable disease. Median progression-free survival was greater than 29 months (OD) and 36.5 months or greater (AO); 86% of patients with OD and 63% with AO remain progression-free. Twenty-four Common Toxicity Criteria Grade 3/4 adverse events were noted.

Address: Department of Neurology, National Neuroscience Institute, Singapore General Hospital Campus, Singapore.

DOI: 10.1212/01.wnl.0000194211.68164.a0

Link outs

Free resources

Medical:

https://medlineplus.gov/braintumors.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Adult, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Asian People, Brain Neoplasms, Dose-Response Relationship, Drug, Female, Humans, Lomustine, Male, Oligodendroglioma, Procarbazine, Survival Analysis, Vincristine